• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

PET Imaging Targeting CXCR4 Shows High Accuracy for Lateralizing Primary Aldosteronism

by
November 13, 2026
in Health
Reading Time: 6 mins read
0
PET Imaging Targeting CXCR4 Shows High Accuracy for Lateralizing Primary Aldosteronism

PET Imaging Targeting CXCR4 Shows High Accuracy for Lateralizing Primary Aldosteronism

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Positron emission tomography using gallium-68 Pentixafor provides high diagnostic accuracy for lateralizing aldosterone-producing lesions in primary aldosteronism, offering an effective non-invasive alternative to adrenal venous sampling. A clinical review in EJNMMI Reports evaluates how targeting chemokine receptor CXCR4 enables functional subtyping of this condition, the most common form of secondary hypertension. Primary aldosteronism accounts for 5 to 10 percent of all hypertension cases. Unlike essential hypertension, autonomous aldosterone secretion causes marked elevations in cardiovascular and cerebrovascular complications, increasing susceptibility to stroke, coronary artery disease, atrial fibrillation, and heart failure. Because timely diagnosis and subtype differentiation guide medical therapy or surgical cure, refining this diagnostic pathway is critical for improving long-term clinical prognosis.

In primary aldosteronism, autonomous hormone secretion escapes regulatory feedback from the renin-angiotensin-aldosterone system. Unregulated aldosterone stimulates epithelial sodium channels in the distal nephron, enhancing sodium reabsorption, expanding plasma volume, and suppressing renin activity. Persistent sodium reabsorption drives arterial hypertension while increasing renal potassium and hydrogen ion excretion, potentially causing hypokalemia and metabolic alkalosis. However, clinical presentations frequently vary, with approximately 80 percent of individuals exhibiting normokalemic hypertension. Initial diagnostic evaluation requires simultaneous measurement of plasma aldosterone concentration and plasma renin activity or direct renin concentration. A suppressed renin state, marked by plasma renin activity at or below 1 nanogram per milliliter per hour or direct renin concentration at or below 8.2 milliunits per liter, alongside plasma aldosterone exceeding 10 nanograms per deciliter and an aldosterone-to-renin ratio greater than 20, indicates primary aldosteronism, which is subsequently confirmed through aldosterone suppression testing.

Following biochemical diagnosis, clinicians must distinguish between unilateral and bilateral disease to guide management. Bilateral adrenal hyperplasia represents 60 to 70 percent of cases and is treated medically with mineralocorticoid receptor antagonists. Conversely, unilateral aldosterone-producing adenomas account for approximately 35 percent of presentations and can be cured through unilateral laparoscopic adrenalectomy. Patients with aldosterone-producing adenomas typically present before age 50 with severe hypertension, marked hypokalemia below 3.2 milliequivalents per liter, and elevated plasma aldosterone concentrations exceeding 25 nanograms per deciliter. Adrenal computed tomography is commonly performed, but anatomical imaging presents notable diagnostic limitations. Functional microadenomas often remain undetectable, while non-functioning macroadenomas in patients over 35 cannot be differentiated from active adenomas. Meta-analytic evidence reveals that computed tomography and magnetic resonance imaging achieve pooled sensitivity of 68 percent and specificity of 57 percent, disagreeing with catheterization in nearly 38 to 50 percent of cases.

To prevent inappropriate surgeries resulting from cross-sectional imaging alone, adrenal venous sampling serves as the established reference standard for confirming aldosterone lateralization. During this invasive procedure, interventional radiologists cannulate the inferior vena cava and adrenal veins under cosyntropin stimulation. Cannulation success requires an adrenal vein-to-inferior vena cava cortisol ratio exceeding 5 to 1, while lateralization is confirmed when the dominant-to-contralateral cortisol-corrected aldosterone ratio exceeds 4 to 1, whereas ratios under 3 to 1 indicate bilateral secretion. Despite its high diagnostic accuracy, adrenal venous sampling faces significant constraints, including procedural invasiveness, substantial costs, limited availability, and risks like groin hematoma. Furthermore, cannulating the small right adrenal vein presents major technical hurdles, resulting in procedural success rates between 50 and 80 percent even in experienced centers. These clinical challenges have accelerated efforts to develop reliable non-invasive molecular imaging alternatives for functional lateralization.

Gallium-68 Pentixafor overcomes these limitations by targeting chemokine receptor CXCR4, a G protein-coupled receptor activated by CXCL12. In normal adrenal tissue, CXCR4 shows high expression in the zona glomerulosa and undergoes prominent upregulation in aldosterone-producing adenomas and cortisol-producing adenomas. Furthermore, CXCR4 expression correlates strongly with CYP11B2, the aldosterone synthase enzyme governing terminal hormone production. In contrast, non-functioning adenomas and paragangliomas display minimal or absent CXCR4 expression. By binding selectively to this upregulated receptor, gallium-68 Pentixafor enables precise functional characterization of adrenocortical tissue, accurately differentiating functional adenomas from non-functioning nodules that compromise conventional imaging assessments.

Clinical investigations summarized in the review confirm the diagnostic accuracy of gallium-68 Pentixafor positron emission tomography across varied cohorts. In an initial proof-of-concept investigation of nine patients, Heinze and colleagues reported 88 percent sensitivity and 87 percent specificity. A retrospective study by Ding and colleagues involving 64 patients demonstrated 97.8 percent sensitivity and 87.5 percent specificity, noting that pheochromocytomas exhibited uptake below normal adrenal levels. In a prospective study of 50 patients by Lu and colleagues, applying a maximum standardized uptake value threshold of 11.95 yielded 74.1 percent sensitivity and 100 percent specificity, with overall concordance reaching 75.7 percent and rising to 96.2 percent in aldosterone-producing adenomas. Furthermore, Hu and collaborators reported 90 percent concordance with adrenal venous sampling in 90 patients, achieving 100 percent agreement among individuals with unilateral nodules exceeding one centimeter on anatomical computed tomography.

A notable clinical advantage of gallium-68 Pentixafor positron emission tomography is its capacity to detect subcentimeter functional lesions that evade anatomical computed tomography. In a prospective cohort of 104 primary aldosteronism patients with micronodules smaller than one centimeter, Ding and colleagues demonstrated that molecular imaging achieved 90.2 percent sensitivity, 72.7 percent specificity, and 86.5 percent overall accuracy for unilateral disease. Across a broader evidence base, a meta-analysis by Gege and colleagues evaluated seven studies encompassing 603 patients. The pooled findings revealed 80 percent sensitivity, 91 percent specificity, and an area under the curve of 0.91 for identifying unilateral primary aldosteronism. The modality agreed with adrenal venous sampling in approximately 79 percent of paired cases, elevating the positive post-test probability of unilateral disease from 75 percent to approximately 96 percent.

Image evaluation combines visual analysis with quantitative standardized uptake metrics. Visual assessment demonstrates high diagnostic accuracy, with reported sensitivities between 74 and 98 percent and specificities between 84 and 100 percent, where positivity requires uptake exceeding the contralateral gland. Semiquantitative metrics provide reproducible validation, with reported maximum standardized uptake value thresholds between 4.5 and 11.95 across published literature. Clinicians also utilize lesion-to-contralateral adrenal ratios and lesion-to-liver ratios ranging from 1.4 to 3.4 to verify lateralization. Uptake intensity displays a clear, statistically significant gradient across adrenal tissue subtypes. Aldosterone-producing adenomas consistently exhibit the highest maximum standardized uptake values, spanning 9 to 14.5, whereas bilateral hyperplasia shows low-to-intermediate uptake between 4 and 6. Non-functioning adenomas and normal adrenal tissue maintain near background levels between 2 and 4, reflecting underlying patterns of CYP11B2 and CXCR4 expression.

The clinical utility of gallium-68 Pentixafor extends directly into surgical guidance, where prospective evaluations show that molecular imaging achieves outcomes non-inferior to adrenal venous sampling. In a single-center prospective cohort of 197 patients evaluated by Zheng and colleagues, 137 patients underwent imaging-guided surgery while 60 underwent sampling-guided surgery. Over a median 27-month follow-up, complete clinical success occurred in 51.5 percent of imaging-guided cases versus 35.1 percent in sampling-guided cases, while biochemical success reached 82.1 percent and 75.4 percent, respectively. Overall benefit rates under established surgical criteria reached 95.5 percent for molecular imaging and 93 percent for venous sampling. Similarly, Tan and colleagues evaluated surgical cohorts undergoing adrenalectomy, documenting biochemical success in 91.3 percent of molecular imaging patients compared to 80.3 percent of venous sampling patients, with surgical cure rates reaching 65.2 percent and 59.1 percent.

Beyond confirming surgical feasibility, uptake intensity provides valuable prognostic insight regarding post-surgical clinical resolution. In a study by Wen-Cai Zheng and colleagues evaluating partial and total adrenalectomy across 90 patients, molecular imaging demonstrated 77.78 percent accuracy in predicting complete biochemical success and 67.78 percent accuracy for complete clinical success, exceeding corresponding venous sampling accuracies of 73.33 percent and 54.44 percent. Notably, when unilateral intense uptake occurs alongside a non-avid contralateral gland, postoperative benefit approaches 100 percent. Elevated uptake values correlate strongly with unilateral disease, lower serum potassium, and larger tumor dimensions, indicating that pronounced receptor expression identifies localized, curable pathology. In contrast, symmetrical uptake of lower intensity characterizes bilateral hyperplasia, directing patients toward medical management with mineralocorticoid receptor antagonists rather than surgery.

Gallium-68 Pentixafor displays a favorable safety and radiation dosimetry profile in clinical practice. A standard injected activity of 150 megabecquerels delivers an effective whole-body dose of approximately 2.3 millisieverts. Critical organ dosimetry demonstrates the highest absorbed doses in the urinary bladder wall at 12.2 milligrays, the spleen at 8.1 milligrays, the kidneys at 5.3 milligrays, and the myocardium at 4.0 milligrays, with lower hepatic and renal exposure than other gallium-based tracers. The agent clears rapidly via renal excretion, with only 4 to 8 percent remaining after four hours. Optimal lesion-to-background contrast develops within 30 minutes, supporting imaging protocols between 30 and 60 minutes post-injection, with Hu and colleagues noting high lateralization accuracy at 10 minutes. Preliminary studies have also investigated technetium-99m-labeled Pentixatec for single-photon emission computed tomography, though large multicenter prospective trials remain necessary to standardize clinical adoption.

Subject of Research: Diagnostic accuracy and surgical utility of 68Ga-Pentixafor PET/CT in primary aldosteronism

Article Title: ⁶⁸GA-Pentixafor PET/CT: a non-invasive molecular alternative to adrenal venous sampling in primary aldosteronism

Article References: Bambhroliya, P., Agrawal, K., Parida, G. K., & Gnanasegaran, G. (2026). ⁶⁸GA-Pentixafor PET/CT: a non-invasive molecular alternative to adrenal venous sampling in primary aldosteronism. EJNMMI Reports, 10(1), Article 14. https://doi.org/10.1186/s41824-026-00287-7

Image Credits: AI Generated

DOI: 10.1186/s41824-026-00287-7

Keywords: primary aldosteronism, 68Ga-Pentixafor, positron emission tomography, adrenal venous sampling, aldosterone-producing adenoma, bilateral adrenal hyperplasia, CXCR4 receptor, CYP11B2, secondary hypertension, adrenalectomy, maximum standardized uptake value, lesion lateralization, adrenal micronodules, radiation dosimetry, 99mTc-Pentixatec, PASO criteria

News Source: Ophelia Keating. (November 13, 2026). PET Imaging Targeting CXCR4 Shows High Accuracy for Lateralizing Primary Aldosteronism. Scienmag.

Tags: 68Ga-pentixafor99mTc-Pentixatecadrenal micronodulesadrenal venous samplingadrenalectomyaldosterone-producing adenomabilateral adrenal hyperplasiaCXCR4 receptorCYP11B2lesion lateralizationmaximum standardized uptake valuePASO criteriapositron emission tomographyprimary aldosteronismradiation dosimetrysecondary hypertension
Share12Tweet7Share2ShareShareShare1

Related Posts

Mixed and Dedifferentiated Endometrial Carcinomas Share Clonal Roots and Hypermutated Backgrounds

Mixed and Dedifferentiated Endometrial Carcinomas Share Clonal Roots and Hypermutated Backgrounds

November 19, 2026
Isometric Handgrip Exercise Fails to Lower Blood Pressure in Trained Hypertensive Women

Isometric Handgrip Exercise Fails to Lower Blood Pressure in Trained Hypertensive Women

November 19, 2026

Three Cell Death Biomarkers May Help Identify Ischemic Stroke in Blood

November 19, 2026

Depth Perception Often Remains Impaired After Central Serous Chorioretinopathy Therapy

November 19, 2026

POPULAR NEWS

  • Corncrake Flagship Status Does Not Guarantee Local Recognition in Rural Romania

    Corncrake Flagship Status Does Not Guarantee Local Recognition in Rural Romania

    29 shares
    Share 12 Tweet 7
  • Pre-Rollout Survey Finds Eighteen Percent HPV Vaccine Uptake Among Chinese College Women

    29 shares
    Share 12 Tweet 7
  • Military Physicians Issue Fewer Medical Exemptions as Decision Fatigue Mounts Across Workdays

    29 shares
    Share 12 Tweet 7
  • Counseling and Mobile App Increase Postpartum Modern Contraceptive Uptake in Jordan

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Mixed and Dedifferentiated Endometrial Carcinomas Share Clonal Roots and Hypermutated Backgrounds

Knowledge Transfer and Blockchain Capability in Saudi Supply Chain Financing

Isometric Handgrip Exercise Fails to Lower Blood Pressure in Trained Hypertensive Women

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.